Wednesday, November 04, 2009

New Zealand To Conduct Seroprevalence Studies

 


# 3954

 

One of the big unknowns about this pandemic virus is how many people are exposed to it, and develop protective antibodies, either with or without falling noticeably ill. 

 

The only way to tell is to do seroprevalence studies; taking blood samples from a representative group of a population and testing them for strain specific antibodies.  

 

New Zealand intends to do just that over the next couple of months, testing 2,500 people randomly selected from across that nation.  This is the kind of scientific study that will tell us a lot about this pandemic virus, and the answers will be eagerly awaited.

 

This media release from the NZ Ministry of Health.

 

 

Media Release

4 November 2009

Study to test pandemic influenza immunity

A study investigating the level of immunity New Zealanders have to pandemic influenza (H1N1) will get underway this month.

 

Blood samples will be taken from 2500 people to see who has been exposed to pandemic influenza and developed immunity to it. This information will be used to establish how many people are still at risk of contracting the illness.

 

The study is being undertaken by Environmental Science and Research (ESR) on behalf of the Ministry of Health.

 

Director of Public Health, Dr Mark Jacobs, says the health sector needs to find out what proportion of the population has already developed immunity to the virus so it can plan more effectively for a possible second pandemic wave.

 

“We know that many people had a mild to moderate illness as a result of pandemic influenza this winter, but we need to get a clearer picture of the general level of immunity and how many people are still at risk. This is because the smaller the proportion of New Zealanders infected so far, the higher the chance of a significant second wave happening in the future.

 

“This is an important study. We hope people will agree to take part in it if they are asked to do so,” says Dr Jacobs. “And people who take part will of course get to find out their own test result”.

 

A two week pilot study is expected to begin within the next few days at a single practice in the Hutt Valley. It will be followed by a nationwide study that will run from later in November until March next year.

 

People randomly selected from participating general practices throughout the country will be asked to take part.

 

The final report is expected in May.